Suppr超能文献

胶质母细胞瘤

Glioblastoma.

作者信息

Miller C Ryan, Perry Arie

机构信息

Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110, USA.

出版信息

Arch Pathol Lab Med. 2007 Mar;131(3):397-406. doi: 10.5858/2007-131-397-G.

Abstract

CONTEXT

Glioblastoma (GBM), the most common primary intracranial malignancy, is a morphologically diverse neoplasm with dismal prognosis despite multimodality therapy. Only 3 distinct morphologic variants of GBM are currently recognized by the current World Health Organization classification scheme, including GBM, giant cell GBM, and gliosarcoma. Additional variants, some of which have significant morphologic overlap with tumors that have more favorable prognosis and treatment response rates, particularly anaplastic oligodendroglioma, have been described since its publication in 2000 and may be included in the next classification.

OBJECTIVE

To summarize the morphologic and molecular genetic diversity of both well-established and novel GBM variants and outline our approach to these heterogeneous neoplasms and their distinction from other diffuse, high-grade gliomas.

DATA SOURCES

Published literature and our own experience in an active academic diagnostic surgical neuropathology practice were reviewed.

CONCLUSIONS

Precise subclassification of GBM is required for accurate prognostication and appropriate treatment planning.

摘要

背景

胶质母细胞瘤(GBM)是最常见的原发性颅内恶性肿瘤,是一种形态多样的肿瘤,尽管采用了多模式治疗,但其预后仍很差。目前世界卫生组织的分类方案仅认可GBM的3种不同形态学变体,包括GBM、巨细胞GBM和胶质肉瘤。自2000年该方案发布以来,已描述了其他变体,其中一些与预后和治疗反应率更有利的肿瘤存在显著形态学重叠,特别是间变性少突胶质细胞瘤,这些变体可能会被纳入下一次分类。

目的

总结已确定的和新的GBM变体的形态学和分子遗传学多样性,并概述我们对这些异质性肿瘤的处理方法以及它们与其他弥漫性高级别胶质瘤的区别。

数据来源

回顾了已发表的文献以及我们在活跃的学术诊断性外科神经病理学实践中的经验。

结论

为了进行准确的预后评估和制定合适的治疗方案,需要对GBM进行精确的亚分类。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验